External Hypofractionated Radiotherapy With Simultaneous Integrated Boost in Early Breast Cancer Patients (ESIBIRE)

R

Regina Elena Cancer Institute

Status and phase

Enrolling
Phase 2

Conditions

Breast Cancer
Breast Neoplasms

Treatments

Radiation: Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost
Radiation: Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost

Study type

Interventional

Funder types

Other

Identifiers

NCT06224244
1652/22

Details and patient eligibility

About

This is a prospective non randomized phase two trial evaluating the feasibility of a ten fraction accelerated hypofractionated radiotherapy schedule with simultaneous integrated boost risk adapted in patients undergoing breast conserving surgery for early breast cancer

Full description

Patients enrolled for the study, according to eligibility criteria, undergo breast conserving surgery followed by adjuvant 10-fraction whole breast irradiation with a risk adapted simultaneous-integrated boost dose at the level of the tumour bed according to clinical and pathological risk factors.

Enrollment

180 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Histologically proven invasive or in situ unifocal adenocarcinoma of the breast
  • Breast conserving surgery
  • Pathological pTis G3, pT1-2 any Grade, pN0 or pN0(sn) (isolated tumor cells [i+] allowed) pN1mic, M0 stage
  • Postoperative negative (no ink) final surgical margins
  • Patient requires a whole breast radiotherapy plus a tumor bed boost
  • Female patients aged ≥ 18 years of any menopausal status
  • ECOG performance status 0-2

Exclusion criteria

  • Past history of malignancy except basal cell skin cancer and CIN cervix uteri or non-breast malignancy allowed if treated with curative intent and at least 5 years' disease free
  • Mastectomy
  • Concomitant chemotherapy (primary or sequential chemotherapy allowed) (Chemotherapy and radiotherapy must be separated by a minimum of 2 weeks). (Patients receiving neo-adjuvant chemotherapy are not excluded)
  • Known disorders associated with a higher risk for complications following radiotherapy such as collagen vascular disease, dermatomyositis, systemic lupus erythematosus or scleroderma
  • Any psychological, familiar, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Any serious uncontrolled medical disorder, non-malignant systemic disease, or active uncontrolled infection. Example include but are not limited to uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction or uncontrolled major seizure disorder
  • Pregnant or lactating patients
  • Presence of ipsilateral breast implant
  • Prior breast or thoracic radiotherapy for any condition

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

180 participants in 2 patient groups

Simultaneous integrated boost to 40 Gy (SIB 40)
Active Comparator group
Description:
Patients with the following clinico-pathological characteristics pTis G3, pT1 pN0/pN1mic, G1-G3 luminal biology or Her-2 positive
Treatment:
Radiation: Ten-fraction hypofractionated breast radiotherapy with 40 Gy simultaneous integrated bed boost
Simultaneous integrated boost to 43 Gy (SIB 43)
Active Comparator group
Description:
Patients with the following clinico-pathological characteristics: Triple negative disease, pT2 pN0/pN1mic, ≤ 50 years not Luminal A
Treatment:
Radiation: Ten-fraction hypofractionated breast radiotherapy with 43 Gy simultaneous integrated bed boost

Trial contacts and locations

1

Loading...

Central trial contact

Silvia Takanen

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems